CSP
2 min read
14

Adopting the final Annual Report

November 11, 2024
0

Reading Time: < 1 minute PHI intends to convene a general meeting to adopt the annual report for the fiscal year 2023/2024 and to amend resolutions regarding election of board members and the number of board members. It has come to the attention of Phase

Continue Reading
CSP
3 min read
20

AnnaCarin Grandin will leave the position as President and CEO of Coor

November 11, 2024
0

Reading Time: 2 minutes After more than four years as President and CEO, AnnaCarin Grandin will leave Coor to take on new challenges outside the company. The Board of Directors will now initiate the process of recruiting a successor. AnnaCarin Grandin will remain in her current

Continue Reading
CSP
1 min read
16

ALEXANDRIA GROUP OYJ: ACQUISITION OF OWN SHARES 11.11.2024

November 11, 2024
0

Reading Time: < 1 minute   ALEXANDRIA GROUP OYJ NOTIFICATION     11.11.2024 at 18:30 EET   ALEXANDRIA GROUP OYJ: ACQUISITION OF OWN SHARES 11.11.2024   Date 11.11.2024   Exchange transaction Buy   Share class ALEX   Amount 250   Average price/share 8.4500 EUR Highest

Continue Reading
CSP
4 min read
22

Recalculation of warrants of series TO5 in Wyld Networks AB

November 11, 2024
0

Reading Time: 3 minutes NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF

Continue Reading
CSP
1 min read
20

#24-388 Delisting of Derivatives from NGM

November 11, 2024
0

Reading Time: < 1 minute Information about certain derivatives that will be delisted from NGM. For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market

Continue Reading
CSP
1 min read
16

Fondia Plc: Share repurchase 11.11.2024

November 11, 2024
0

Reading Time: < 1 minute Fondia Plc Company release 11.11.2024 at 6.45 p.m. EET   Fondia – Acquisition of own shares 11.11.2024   Fondia Plc   First North Finland   Date 11.11.2024 Exchange transactions Buy Share class FONDIA Amount, shares 93 Average price/share, EUR 5,936559

Continue Reading
CSP
1 min read
13

#24-387 Listing of Derivatives at NGM

November 11, 2024
0

Reading Time: < 1 minute Information about various derivatives that will be listed at NGM. For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market

Continue Reading
CSP
1 min read
16

Wärtsilä President & CEO Håkan Agnevall on sick leave until 25 November

November 11, 2024
0

Reading Time: < 1 minute Wärtsilä Corporation, Stock exchange release, 11 November 2024 at 17.00 EET Wärtsilä President & CEO Håkan Agnevall on sick leave until 25 November Wärtsilä’s President & CEO Håkan Agnevall will be on sick leave due to a planned routine surgery

Continue Reading
Vedanta Ltd. Reports Highest-Ever 1H EBITDA at .47 Billion
BWI
3 min read
32

Vedanta Ltd. Reports Highest-Ever 1H EBITDA at $2.47 Billion

November 11, 2024
0

Reading Time: 2 minutes Indian multinational, Vedanta Limited (“Vedanta”) (NSE: VEDL), world’s leading critical and future minerals, energy and technology conglomerate announced its results for Q2 and H1 ending September 30, 2024. It reported highest-ever 1H EBITDA at $2.47 billion, up 46% YoY1. The company’s Q2 consolidated revenue was $4.4

Continue Reading
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
BWI
4 min read
30

Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

November 11, 2024
0

Reading Time: 3 minutes Beijing, China & South San Francisco, Calif., United States:   IDEAYA has exercised the option for an exclusive worldwide license on Biocytogen’s potential first-in-class B7H3/PTK7 topo-I-payload bispecific antibody-drug conjugate (BsADC), BCG034 (IDE034) This milestone further validates Biocytogen’s proprietary RenLite® antibody

Continue Reading